Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DE-ESCALATE

Financiado

INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWA...

INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of five prostate cancer patients will die from their disease. Despite progress in the past y... ver más

31/05/2028

EORTC

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

EUROPEAN ORGANISATION FOR RESEARCH AND TREATM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-21

HORIZON-MISS-2022-CANCER-01-03: Pragmatic clinical trials to optimi... ExpectedOutcome:While cancer research and innovation have generated novel treatment options, cancer...

I+D

Cerrada hace 2 años

0% 100% 100%

6 Participantes

EORTC

6.27M€ | Lider

EUROPA UOMO

100.00K€ | Participante

MINISTERE DE L'ENSEIGNEMENT...

100.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNS2023-144975 Cáncer 200K€ Cerrado

RTI2018-101500-B-I00 BASES ESTRUCTURALES DE LAS INTERACCIONES DEL RECEPTOR DE AND... 145K€ Cerrado

RTI2018-096055-B-I00 DETECCION TEMPRANA DE RECURRENCIA PARA UNA TERAPIA PERSONALI... 109K€ Cerrado

BFU2017-86906-R ONCOLOGIA ESTRUCTURAL DEL RECEPTOR DE ANDROGENOS: ARQUITECTU... 125K€ Cerrado

PDC2021-121688-I00 INHIBIDORES DE LA DIMERIZACION DEL RECEPTOR DE ANDROGENOS CO... 144K€ Cerrado

MetaboMARKER A metabolism based prognostic biomarker for prostate cancer 150K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2023-04-21
Fecha Fin: 2028-05-31

Líder del proyecto

EUROPEAN ORGANISATION FOR RESEARCH AND TREATM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Descripción del proyecto Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of five prostate cancer patients will die from their disease. Despite progress in the past years, it remains critical to improve on the present strategy for advanced and metastatic prostate cancer. Within the proposed project, we will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit while minimizing side effects and resource utilization and improving patient quality of life. The proposed clinical trial is designed to detect early if iADT has a negative impact on overall survival compared to continuous therapy. If successful, the outcomes of the project will define a new evidence-based standard of care for metastatic hormone sensitive prostate cancer. The proposed research could lead to improved patient survival and quality of life but also improve health system sustainability. This is a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores